Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to strengthen its team of top-tier talent as it prepares to launch specialized pharmaceutical and nutraceutical cannabinoid products. These efforts align with the company’s mission to improve the quality of life for individuals with chronic, degenerative, and life-threatening illnesses while driving advancements in modern medicine through innovative solutions, such as mRNA vaccines for cancer and other widespread diseases.
As product launches approach and 13 medical patents are submitted to the USPTO, the firm is focused on enhancing production and research capabilities to position itself as an attractive partner for larger pharmaceutical firms. The company is committed to leading the development of scientifically validated therapeutic cannabinoid solutions, leveraging potential opportunities from cannabis reclassification and has added several professionals to its R&D team.
Shares were trading higher in late morning trade.
Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View the original article on AllPennyStocks.com
]]>